theheart.org: Thrombosis Risk news and education

Thrombosis Risk

Uncertainty remains as to whether genetic testing for VTE improves outcomes

1 COMMENT - Jun 19, 2009 12:00 EDT

It remains unknown whether genetic testing for two prothrombotic mutations improves outcomes for patients with venous thromboembolism or for family members of those with mutations, a new review concludes.

Baltimore, MD - There is insufficient evidence to conclude that genetic testing for two prothrombotic mutations improves outcomes for patients with venous thromboembolism (VTE) or for family members of people who carry the mutations, a new review has found [1]. Dr Jodi B Segal (Johns Hopkins University School of Medicine, Baltimore, MD) and colleagues report their findings in the June 17, 2009 issue of the Journal of the American Medical Association. Read full article »

Inside: Thrombosis Risk

Accredited educational programs, supported by industry, developed by theheart.org

Thrombosis Risk

Total Joint Arthroplasty: Cutting Edge Developments in the Prevention of Thromboembolism

Jan 12, 2009 13:55 EST

The balancing act: How can we best protect patients from thromboembolic complications after major orthopaedic surgery without increasing the risk of bleeding? Drs Caprini, Maloney, and Barnes discuss management strategies and unmet needs in treatment options.

Thrombosis Risk

Warfarin and Beyond: Evolution of Anticoagulation Therapies

12 COMMENTS - Dec 29, 2008 15:45 EST

Where do the new and emerging oral anticoagulants target the coagulation cascade and how will they impact thromboprophylaxis in a variety of clinical settings. Join Drs Turpie and Weitz as they discuss the limitations of existing therapies and new developments in finding a replacement.

Thrombosis Risk

North American Thrombosis Forum (NATF)

3 COMMENTS - Jan 12, 2009 02:02 EST

NATF's vision is to improve patient care, outcomes, and public health by utilizing a multidisciplinary approach to advance thrombosis research and education. NATF's legacy will be the improvement of patient care, outcomes, and public health by supporting thrombosis-related programs, such as novel research projects, innovative educational programs, public policy initiatives, regulatory issues and advocacy. NATF also seeks to broaden training opportunities for physicians, scientists, and other health professionals.

Acute Coronary Syndromes

Prevention of Arterial Thrombosis, a Review of Agents in Development

Sep 15, 2008 09:33 EDT

Join Drs Mahaffey, Hylek, Wallentin, and Weitz as they discuss the mechanisms by which various antithrombotic therapies target the coagulation cascade, the efficacy and safety of the currently available agents, and promising results from clinical trials of novel agents.

Lipid/Metabolic

New meta-analysis: Statins of benefit in primary prevention

9 COMMENTS - Jun 30, 2009 19:01 EDT

A new meta-analysis including some of the more contemporary statin trials has found that the agents significantly improve survival and reduce coronary and cardiovascular end points in primary-prevention populations, a benefit that extends to all subgroups. But the exact cost/benefit equation for each group remains to be determined.

Hypertension

Wolves in sheep's clothing: Don't ignore white-coat and masked hypertension

1 COMMENT - Jun 29, 2009 16:00 EDT

White-coat hypertension and masked hypertension should not be regarded as benign, say the authors of a new 10-year study. The risk of developing sustained hypertension is higher in people with the above two conditions than in those who have normal blood pressure, they found.

Acute Coronary Syndromes

TRANSFER AMI published: Finding the optimal window for PCI postlysis

Jun 25, 2009 13:45 EDT

Experts suggest that early PCI is beneficial in STEMI patients already treated with fibrinolysis, as long as it is performed at least two hours after the lytic is given.

Arrhythmia/EP

Wide variations in EP practice across Europe

Jun 24, 2009 15:30 EDT

The way in which arrhythmias are treated varies greatly across Europe, a new survey of 40 countries has shown.

Acute Coronary Syndromes

CV mortality and hospitalizations declining in Canada

Jun 22, 2009 16:30 EDT

From 1994 to 2004, cardiovascular disease mortality declined 30%, while the rate of MI mortality decreased 38.1% and stroke mortality decreased 28.2%.

Clinical cardiology

Psoriasis associated with all vascular disease

5 COMMENTS - Jun 22, 2009 13:45 EDT

As well as being an independent risk factor for cardiovascular disease, psoriasis is also associated with an increased risk of cerebrovascular disease and peripheral arterial disease, a new case-control study has shown.

Acute Coronary Syndromes

EMEA issues warning on possible clopidogrel-PPI interaction, but is there really a problem?

2 COMMENTS - Jun 19, 2009 14:00 EDT

The European Medicines Agency has now followed suit with the US FDA and issued a warning discouraging concomitant use of clopidogrel and PPIs, but some experts believe the issue has been overhyped.

Hypertension

New low-cost, solar-powered BP device for developing countries

Jun 18, 2009 15:15 EDT

A new, low-cost, solar-powered blood-pressure-monitoring device has been shown to be accurate and easy to use and was well accepted by healthcare professionals and patients in a field trial in Africa. This could be a "critical tool" in tackling the global problem of hypertension, said one expert.

Hypertension

A Portuguese success story: One nation begins to curb its salt intake

6 COMMENTS - Jun 18, 2009 10:00 EDT

Doctors from the Portuguese Society of Hypertension have spearheaded a unique mass-media campaign about the harmful consequences of consuming too much salt, which in turn has led to the Portuguese Parliament approving a law restricting the sodium content of processed foods.

Acute Coronary Syndromes

Published ATLAS ACS-TIMI 46 results for rivaroxaban pave the way for phase 3 trial

1 COMMENT - Jun 17, 2009 14:30 EDT

Investigators say results from this phase 2, dose-escalation study have paved the way for the phase 3 trial, ATLAS ACS 2, already enrolling patients and using the lower two doses, twice daily, identified as having the most desirable risk/benefit profile in the phase 2 study.

Hypertension

Darusentan data encouraging but "very, very early"

Jun 16, 2009 14:30 EDT

A phase 3 study with darusentan in patients with resistant hypertension was encouraging, but the data are still "very, very early," said the researcher who presented the late-breaking trial at the European Hypertension meeting this weekend.

The Clotblog

Rosuvastatin in the Prevention of Venous Thromboembolism

May 29, 2009

View all »

Editorial Programs

Editorial series

Life and times of leading cardiologists with Rob Califf. Guest: Steve Nissen

1 COMMENT - Jun 1, 2009 10:20 EDT

Join Dr Robert Califf for a probing and personal interview with Dr Steven Nissen, about his activist days at the University of Michigan and the development of IVUS, to how he ended up at the Cleveland Clinic and what he thinks about the future of medicine in America.

The Cardiology Show

ACC 2009: From the eye of the storm in Orlando

Apr 2, 2009 15:35 EDT

Join Drs Valentin Fuster, Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf as they unravel the STICH trial and debate the lessons learned from PROTECT-AF in Part 1 of the Cardiology Show. In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.

Cardiology panels

SYNTAX at one year: Deciphering the data

Oct 3, 2008 13:40 EDT

Drs Antonio Colombo and Renu Virmani talk about the one-year results of the SYNTAX trial, the importance of understanding registries, and the complex issue of clopidogrel duration with drug-eluting stents in a discussion moderated by heartwire journalist Shelley Wood.

	Yes
	No